Oncology leaders use real-world evidence to help curb a lack of diversity in clinical trials
- One issue that leads to disparities between trial populations and the general population is the use of stringent eligibility criteria in clinical trials. Real-world patients may have comorbidities and other traits that can lead to their exclusion from cancer trials that are designed for maximum clarity of data
- The FDA’s 2018 Drug Trials Snapshots showed that of the more than 5000 patients that year who participated in oncology trials that led to approvals, just 4% were Black and 4% were Hispanic, despite the fact that 13.4% of the US population was Black and 18.1% was Hispanic
- Women were also under-represented: They made up 38% of the trial population but 51% of the US population. At the same time, Asian patients were overrepresented, making up 15% of the trial population but just 5.8% of the US population
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.